Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Johnson and Johnson
Merck
Harvard Business School
Boehringer Ingelheim

Last Updated: February 2, 2023

NARCAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Narcan patents expire, and what generic alternatives are available?

Narcan is a drug marketed by Adapt, Bristol Myers Squibb, and Emergent. and is included in five NDAs. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-eight patent family members in fourteen countries.

The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

Drug patent expirations by year for NARCAN
Drug Prices for NARCAN

See drug prices for NARCAN

Recent Clinical Trials for NARCAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Alabama at BirminghamPhase 4
Vanderbilt University Medical CenterEarly Phase 1
Rush University Medical CenterEarly Phase 1

See all NARCAN clinical trials

Pharmacology for NARCAN
Drug ClassOpioid Antagonist
Mechanism of Action Opioid Antagonists
Paragraph IV (Patent) Challenges for NARCAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NARCAN Nasal Spray naloxone hydrochloride 2 mg/spray 208411 1 2017-12-28
NARCAN Nasal Spray naloxone hydrochloride 4 mg/spray 208411 1 2016-07-15

US Patents and Regulatory Information for NARCAN

NARCAN is protected by eight US patents.

Patents protecting NARCAN

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Nasal drug products and methods of their use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Adapt NARCAN naloxone hydrochloride INJECTABLE;INJECTION 016636-002 Approved Prior to Jan 1, 1982 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Emergent NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411-002 Jan 24, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Bristol Myers Squibb NARCAN naloxone hydrochloride INJECTABLE;INJECTION 071083-001 Jul 28, 1988 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NARCAN

See the table below for patents covering NARCAN around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2017049181 See Plans and Pricing
Israel 279001 תרופות לאף ושיטות שימוש בהן (Nasal drug products and methods of their use) See Plans and Pricing
European Patent Office 3777838 PRODUITS DE MÉDICAMENT NASAL ET LEURS PROCÉDÉS D'UTILISATION (NASAL DRUG PRODUCTS AND METHODS OF THEIR USE) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NARCAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1685839 92292 Luxembourg See Plans and Pricing PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Colorcon
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.